NEO Stock Overview
Operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NeoGenomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.36 |
| 52 Week High | US$21.22 |
| 52 Week Low | US$12.77 |
| Beta | 1.18 |
| 11 Month Change | 16.98% |
| 3 Month Change | -5.19% |
| 1 Year Change | -19.56% |
| 33 Year Change | -59.18% |
| 5 Year Change | -40.47% |
| Change since IPO | 490.77% |
Recent News & Updates
Recent updates
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Oct 16
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%
Aug 01Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Jul 15Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues
Mar 30Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking
Dec 26Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Aug 23Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)
Jul 16NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt
Apr 18We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt
Jan 10NeoGenomics: Market Punishment Continues, But Looks Justified
Sep 30NeoGenomics grants CEO restricted shares, stock options
Aug 17Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Aug 10NeoGenomics rises ~14% on strong Q2 result
Aug 09NeoGenomics gets new CEO
Jul 21NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential
Jun 28Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?
Apr 22Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral
Apr 08Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching
Feb 11Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?
Jan 07NeoGenomics: Gambling On Growth
Dec 16Shareholder Returns
| NEO | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -6.5% | -4.6% | -1.2% |
| 1Y | -19.6% | 1.1% | 30.4% |
Return vs Industry: NEO underperformed the US Healthcare industry which returned 1.1% over the past year.
Return vs Market: NEO underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| NEO volatility | |
|---|---|
| NEO Average Weekly Movement | 5.6% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NEO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NEO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,100 | Chris Smith | www.neogenomics.com |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
NeoGenomics, Inc. Fundamentals Summary
| NEO fundamental statistics | |
|---|---|
| Market cap | US$1.97b |
| Earnings (TTM) | -US$77.73m |
| Revenue (TTM) | US$644.12m |
3.1x
P/S Ratio-25.4x
P/E RatioIs NEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEO income statement (TTM) | |
|---|---|
| Revenue | US$644.12m |
| Cost of Revenue | US$363.69m |
| Gross Profit | US$280.43m |
| Other Expenses | US$358.16m |
| Earnings | -US$77.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 43.54% |
| Net Profit Margin | -12.07% |
| Debt/Equity Ratio | 59.5% |
How did NEO perform over the long term?
See historical performance and comparison